menu
{ "item_title" : "Racing to a Cure", "item_author" : [" Neil Ruzic "], "item_description" : "Racing to a Cure is not a cancer memoir. It is a cancer cure memoir. In 1998 Neil Ruzic was diagnosed with mantle-cell lymphoma, the deadliest cancer of the lymph system, whose spread is reaching epidemic levels in the U.S. and Europe. Instead of following recommended courses of chemotherapy and radiation, he took control of his treatment by investigating cures being developed in the nation's cancer-research laboratories. Although chemotherapy harms the immune system and is increasingly demonstrated to be an ineffective long-term cure for the vast majority of cancers, it remains the standard treatment for most cancer patients. Ruzic, a former scientific magazine publisher and originator of a science center, refused to accept this status quo, and instead plunged into the world of cutting-edge treatments, exploring the frontiers of cancer science with revolutionary results. Ruzic went on the offensive: visiting scores of laboratories, gathering information, talking to researchers, and effectively becoming his own patient-care advocate. This book presents his findings. A scathing critique of the chemotherapy culture as well as unscientific alternative therapies, the book endorses state-of-the-art molecularly based technologies, making it an illuminating and necessary read for anyone interested in cancer research, especially patients and their families and physicians. Neil Ruzic was expected to die within two years of his initial diagnosis. Five years later he has been declared cancer-free and considers himself cured. ", "item_img_path" : "https://covers4.booksamillion.com/covers/bam/0/25/207/357/0252073576_b.jpg", "price_data" : { "retail_price" : "20.95", "online_price" : "20.95", "our_price" : "20.95", "club_price" : "20.95", "savings_pct" : "0", "savings_amt" : "0.00", "club_savings_pct" : "0", "club_savings_amt" : "0.00", "discount_pct" : "10", "store_price" : "" } }
Racing to a Cure|Neil Ruzic

Racing to a Cure : A Cancer Victim Refuses Chemotherapy and Finds Tomorrow's Cures in Today's Scientific Laboratories

local_shippingShip to Me
On Order. Usually ships in 2-4 weeks
FREE Shipping for Club Members help

Overview

Racing to a Cure is not a cancer memoir. It is a cancer cure memoir. In 1998 Neil Ruzic was diagnosed with mantle-cell lymphoma, the deadliest cancer of the lymph system, whose spread is reaching epidemic levels in the U.S. and Europe. Instead of following recommended courses of chemotherapy and radiation, he took control of his treatment by investigating cures being developed in the nation's cancer-research laboratories.

Although chemotherapy harms the immune system and is increasingly demonstrated to be an ineffective long-term cure for the vast majority of cancers, it remains the standard treatment for most cancer patients. Ruzic, a former scientific magazine publisher and originator of a science center, refused to accept this status quo, and instead plunged into the world of cutting-edge treatments, exploring the frontiers of cancer science with revolutionary results.

Ruzic went on the offensive: visiting scores of laboratories, gathering information, talking to researchers, and effectively becoming his own patient-care advocate. This book presents his findings. A scathing critique of the chemotherapy culture as well as unscientific "alternative" therapies, the book endorses state-of-the-art molecularly based technologies, making it an illuminating and necessary read for anyone interested in cancer research, especially patients and their families and physicians.

Neil Ruzic was expected to die within two years of his initial diagnosis. Five years later he has been declared cancer-free and considers himself cured.

Details

  • ISBN-13: 9780252073571
  • ISBN-10: 0252073576
  • Publisher: University of Illinois Press
  • Publish Date: March 2006
  • Dimensions: 8.98 x 6.1 x 1.07 inches
  • Shipping Weight: 1.37 pounds
  • Page Count: 456

Related Categories

You May Also Like...

    1

BAM Customer Reviews